Leuprolide
Also known as: Eligard, Leuprolide, Leuprolide acetate, Leuprorelin, Lupron, Lupron Depot, TAP-144, Viadur
Source Leuprolide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Leuprolide is a synthetic GnRH agonist approved for injectable use. It is employed to relieve endometriosis‑related pelvic pain and as androgen‑deprivation therapy for prostate cancer by suppressing ovarian estrogen or testicular testosterone production. Formulations include intramuscular, subcutaneous depot injections and subcutaneous implants.
Mechanism of Action
Leuprolide mimics natural GnRH and binds pituitary GnRH receptors. Continuous stimulation causes receptor desensitization and down‑regulation, sharply reducing luteinizing‑hormone (LH) and follicle‑stimulating hormone (FSH) secretion. The resulting drop in ovarian estrogen or testicular testosterone creates a hypo‑gonadal state. An initial transient rise in gonadotropins (flare) precedes the sustained suppression.
What the Research Shows
A 2025 network meta‑analysis of 31 randomized trials (8,665 participants) showed leuprolide alone significantly reduced endometriosis‑associated pelvic pain versus placebo (standardized mean difference −1.05). In the phase 3 HERO trial for advanced prostate cancer, leuprolide achieved castrate testosterone in 88.8 % of men at 48 weeks, but suppression was slower than with the GnRH antagonist relugolix and was linked to a higher rate of major adverse cardiovascular events (6.2 % vs 2.9 %). In the EMBARK studies of high‑risk biochemical recurrence, leuprolide served as the control arm; combination with enzalutamide improved 8‑year overall survival (78.9 % vs 69.5 %) and metastasis‑free survival (87.3 % vs 71.4 %). These data confirm leuprolide’s efficacy for symptom control and hormone suppression while highlighting limitations relative to newer regimens.
Reported Benefits
Leuprolide reliably lowers estrogen in women, providing clinically meaningful relief of endometriosis‑related pelvic pain. In men, it produces sustained testosterone suppression sufficient for androgen‑deprivation therapy, contributing to disease control in prostate cancer when used alone or as a backbone for combination therapy. Depot formulations allow dosing intervals from one to six months, enhancing adherence.
Limitations of the Evidence
The drug induces an initial hormone surge that may temporarily worsen symptoms before suppression occurs. Compared with GnRH antagonists, leuprolide achieves slower testosterone lowering and shows a higher incidence of major cardiovascular events. As monotherapy in prostate cancer, it yields inferior overall and metastasis‑free survival versus enzalutamide‑based combinations. No data on ovarian endometriomas are presented in the cited literature, and long‑term safety beyond cardiovascular outcomes remains incompletely defined.
Safety Considerations
Leuprolide’s continuous GnRH receptor activation leads to a transient flare in gonadotropins, potentially aggravating pain or tumor activity. Clinical trials reported a 6.2 % incidence of major adverse cardiovascular events in men receiving leuprolide versus 2.9 % with an antagonist. While not detailed in the provided abstracts, GnRH agonists are known to cause hot flashes, bone‑density loss, and injection‑site reactions; these should be monitored. Cardiovascular risk assessment and bone health surveillance are advisable during treatment.
How It Is Administered
Leuprolide is given by injection—intramuscular or subcutaneous depot preparations with dosing intervals ranging from monthly to quarterly, and as a subcutaneous biodegradable implant delivering drug over several months. All formulations are prescription‑only.
Routes of Administration
Goals & Uses
- Central precocious puberty (CPP)Pediatric EndocrinologyHigh
- Assisted reproduction (controlled ovarian hyperstimulation)ReproductiveModerate
- Prostate cancer (hormone-sensitive, advanced)OncologyHigh
- Prostate cancerOncologyHigh
- Central precocious pubertyPediatric EndocrinologyHigh
- Uterine fibroidsGynecologyModerate
- Uterine fibroids (leiomyomata)GynecologyHigh
- Assisted reproduction (controlled ovarian stimulation)Reproductive MedicineModerate
- Gender-affirming hormone therapy (puberty suppression)EndocrinologyModerate
- EndometriosisGynecologyHigh
Contraindications
- Undiagnosed vaginal bleedingGynecologicalHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- BreastfeedingPopulationHighPotential transfer into breast milk or insufficient safety data
- Hypersensitivity to GnRH analogues or excipientsImmunologicHigh
- Spinal cord compression risk (prostate cancer)OncologyHigh
- Known hypersensitivity to leuprolide or formulation excipientsGeneralModerate
Adverse Effects
- Hot flashes / vasomotor symptomsAutonomic / ThermoregulatoryCommon
- Mood changesPsychiatricUncommon
- Testosterone/estrogen flare (initial)EndocrineCommon
- Injection site reactionsLocalCommon
- Injection site painLocalCommonPain at the injection site
- Sexual dysfunction (decreased libido, erectile dysfunction)Sexual HealthCommon
- Decreased libidoSexual / EndocrineCommon
- Hot flashesEndocrine / VasomotorCommon
- Bone mineral density loss / osteoporosisMusculoskeletalCommon
- QT/QTc prolongationCardiovascularUncommon
- Bone mineral density lossSkeletalUncommon
Drug Interactions
- CYP3A4 inhibitors (e.g., ketoconazole)Low
- Estrogen replacement therapyModerate
- Antidiabetic agents (insulin, sulfonylureas)Moderate
- QT-prolonging agents (e.g., antiarrhythmics, antipsychotics)High
- Anticoagulants (warfarin)Moderate
Population Constraints
- Elderly patients with osteoporosisComorbidityRelative
- Pediatric patients (outside CPP indication)AgeRelative
- Patients with osteoporosis or high fracture riskMusculoskeletalRelative
- Patients with pre-existing cardiovascular diseaseCardiovascularRelative
- Patients with depression or psychiatric disordersPsychiatricRelative
- Pediatric patients <2 yearsAgeRelative
Regulatory Status
- European UnionApprovedApproved: Prostate cancer, Endometriosis, Uterine fibroids, Central precocious pubertyEMA‑approved; marketed under multiple brand names.
- United StatesApprovedApproved: Prostate cancer, Endometriosis, Uterine fibroids, Central precocious puberty, Assisted reproductionFDA‑approved; prescription only.
- United KingdomApprovedApproved: Prostate cancer, Endometriosis, Uterine fibroids, Central precocious pubertyMHRA‑approved; prescription required.
Approved by FDA (US), EMA (EU) and MHRA (UK) for multiple endocrine‑related indications.
Evidence & Sources
- Journal ArticleHighKou L, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleModerateShore ND, et al.2020-01-01T00:00:00.000000Z
- Journal ArticleModerateShore ND, et al.2026-01-01T00:00:00.000000Z
- Journal ArticleModerateFreedland SJ, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleHighThiel PS, et al.2024-01-01T00:00:00.000000Z
Frequently Asked Questions
What medical conditions is leuprolide prescribed for?
Leuprolide is approved for hormonal management of endometriosis‑related pelvic pain and as androgen‑deprivation therapy in prostate cancer, where it suppresses estrogen or testosterone production.
How does leuprolide lower hormone levels?
By continuously stimulating pituitary GnRH receptors, leuprolide causes receptor down‑regulation, leading to a marked decrease in LH and FSH release, which in turn reduces ovarian estrogen or testicular testosterone output.
How quickly does leuprolide achieve testosterone suppression in men?
In the HERO trial, 56 % of men receiving leuprolide reached castrate testosterone levels by day 4, and 88.8 % maintained castration through 48 weeks; suppression is slower than with GnRH antagonists.
What are the main safety concerns with leuprolide?
Leuprolide can cause an initial hormone flare, and clinical data show a higher rate of major cardiovascular events (6.2 % vs 2.9 % with an antagonist). Monitoring for cardiovascular risk and bone health is recommended.
How is leuprolide administered?
It is delivered as an intramuscular or subcutaneous depot injection (monthly, quarterly, or longer intervals) or as a subcutaneous implant that releases drug over several months.
What is Leuprolide?
Leuprolide is a synthetic GnRH agonist approved for injectable use. It is employed to relieve endometriosis‑related pelvic pain and as androgen‑deprivation therapy for prostate cancer by suppressing ovarian estrogen or testicular testosterone production. Formulations include intramuscular, subcutaneous depot injections and subcutaneous implants.
What is Leuprolide used for?
Leuprolide is educationally associated with: Central precocious puberty (CPP), Assisted reproduction (controlled ovarian hyperstimulation), Prostate cancer (hormone-sensitive, advanced), Prostate cancer, Central precocious puberty, Uterine fibroids, Uterine fibroids (leiomyomata), Assisted reproduction (controlled ovarian stimulation), Gender-affirming hormone therapy (puberty suppression), Endometriosis. Educational only — not medical advice.
How is Leuprolide administered?
Recorded routes of administration: Intramuscular, Subcutaneous, Subcutaneous Implant.
What are the potential side effects of Leuprolide?
Reported adverse effects include: Hot flashes / vasomotor symptoms, Mood changes, Testosterone/estrogen flare (initial), Injection site reactions, Injection site pain, Sexual dysfunction (decreased libido, erectile dysfunction), Decreased libido, Hot flashes, Bone mineral density loss / osteoporosis, QT/QTc prolongation, Bone mineral density loss. This list is not exhaustive — consult a qualified clinician.
Who should avoid Leuprolide?
Recorded contraindications: Undiagnosed vaginal bleeding, Pregnancy, Breastfeeding, Hypersensitivity to GnRH analogues or excipients, Spinal cord compression risk (prostate cancer), Known hypersensitivity to leuprolide or formulation excipients. Consult a qualified clinician before use.